Clinical trials: Methamphetamine
Methamphetamine Dependence
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
- Trial name
- NCT00730522
- Testing
- CPP-109 vigabatrin
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Methamphetamine-dependence, Methamphetamine Abuse
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder.
- Trial name
- OUTLAST (NCT05034874)
- Testing
- IXT-m200
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- InterveXion Therapeutics, LLC
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Methamphetamine Intoxication (Disorder)
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
The hypothesis of this multisite Phase 2a study is that IXT-m200 will be well-tolerated in patients with acute mild to moderate METH toxicity.
- Trial name
- Meth-OD (NCT04715230)
- Testing
- IXT-m200, Lorazepam, Haloperidol
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InterveXion Therapeutics, LLC
Methamphetamine-dependence, Methamphetamine Abuse
Study of Antibody for Methamphetamine Outpatient Therapy
This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels.
- Trial name
- STAMPOUT (NCT03336866)
- Testing
- IXT-m200
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- InterveXion Therapeutics, LLC